P592: GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

P592: GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	A. Žučenka, R. Pileckytė, K. Maneikis, V. Vaitekėnaitė, L. Kevličius, L. Griškevičius
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845256.68897.e2

Similar Items

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
by: Andrius Žučenka, et al.
Published: (2023-08-01)

Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
by: Rabia Shahswar, et al.
Published: (2023-07-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
by: Nickolas Steinauer, et al.
Published: (2024-03-01)

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms
by: Man Li, et al.
Published: (2024-08-01)

P454: VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING
by: C. Schmidt, et al.
Published: (2022-06-01)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
by: Linyu Yuan, et al.
Published: (2023-08-01)

Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD–positive acute myeloid leukemia
by: Hyun Don Yun, et al.
Published: (2019-11-01)

P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS
by: S. Shimony, et al.
Published: (2022-06-01)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
by: Alexander E. Perl, et al.
Published: (2022-05-01)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
by: Jessica K. Altman, et al.
Published: (2021-02-01)

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
by: Yan-Yan Li, et al.
Published: (2024-01-01)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-10-01)

A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
by: Ke-xin Li, et al.
Published: (2022-03-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION
by: Chen Liang, et al.
Published: (2023-08-01)

Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly
by: Masuho Saburi, et al.
Published: (2023-01-01)

P554: GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL IN ASIA
by: J. Wang, et al.
Published: (2022-06-01)

Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
by: Ke-xin Li, et al.
Published: (2022-06-01)

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
by: Ramzi Abboud, et al.
Published: (2020-08-01)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
by: Jan Philipp Bewersdorf, et al.
Published: (2020-01-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
by: Andrea Duminuco, et al.
Published: (2022-09-01)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
by: Bocchia M, et al.
Published: (2022-04-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

PB1850: A DOSE FINDING AND EXPANSION OPEN LABEL, MULTICENTER STUDY OF IADADEMSTAT AND GILTERITINIB IN PATIENTS WITH RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA WITH MUTATED FLT3: THE FRIDA STUDY
by: A. Fathi, et al.
Published: (2022-06-01)

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
by: Qingyang Liu, et al.
Published: (2025-03-01)

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2018-09-01)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
by: Andrius Žučenka, et al.
Published: (2023-08-01)

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
by: Qi Zhou, et al.
Published: (2025-02-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

A real-world study on Clofarabine and Cytarabine combination in patients with relapsed/refractory acute myeloid leukemia
by: Claudio Fozza, et al.
Published: (2019-04-01)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
by: Abhishek Maiti, et al.
Published: (2021-02-01)

P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY
by: D. Quintela, et al.
Published: (2022-06-01)

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
by: Abhishek Maiti, et al.
Published: (2020-06-01)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
by: Nerea Báez-Gutiérrez, et al.
Published: (2021-08-01)

Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia <i>FLT3</i>-ITD patients
by: Nicolas Vignal, et al.
Published: (2023-02-01)